HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases INMB INVESTOR PRESENTATION January 2020
FORWARD LOOKING STATEMENTS This presentation contains “forward -looking statements” Forward-looking statements reflect our current view about future events. When used in this presentation, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this presentation relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward – looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. There is no guarantee that any specific outcome will be achieved. Investment results are speculative and there is a risk of loss, potentially all loss of investments. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. 2
Nasdaq INVESTMENT SUMMARY INMB Cash (9/30/19) $7.4 Million Immunology company, advancing through Phase I and Phase II clinical trials ▪ Debt $0 Two platforms with novel approaches to inflammation, neurodegenerative disease and oncology ▪ Common Shares Dominant Negative Tumor Necrosis Factor (DN-TNF) PLATFORM Immune Priming PLATFORM 10.8 Million Inside Ownership ~50% INB03™ & INKmune™ - Resistance to cancer immunotherapy by altering the TME and triggering NK cells XPro1595™ - Neuroinflammation as a cause of neurodegenerative disease LIVNate ™ - Pleiotropic therapy for NASH 2020: Two Phase II programs, one Phase I readout and two Phase I program planned Notable Shareholder ▪ Xencor (XNCR) Over 65 publications from multiple universities worldwide on both platforms with extensive ▪ in vivo data Xencor Option $10m @ 100m Strike Efficient use of capital including non-dilutive sources ▪ price for 10% of INMB Exp. ~ 4 years Experienced management team ▪ 3
MANAGEMENT TEAM TEAM PEDEGREE Raymond J. Tesi, MD, CEO/CMO & Chairman of the Board Dr. Tesi has been our President, Chief Executive Officer and acting Chief Medical Officer since the formation of the Company in September 2015. From November 2011 to May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development-stage biotech company formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech company in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was CEO and President of Coronado Biosciences, a company he founded. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982 and Fellow of the American College of Surgery since 1991. David J. Moss, CFO Mr. Moss has been CFO since the formation of the Company in September 2015. Mr. Moss has founded, funded and taken public various companies in a variety of industries since 1995. Mr. Moss sits on the board of CareSpan International, Inc. and China Xiangtai Food Co. Ltd (Nasdaq: PLIN) and also serves as chair of their Audit Committee. Mr. Moss was a founding investor in Reliant Service Group LLC, which was acquired in 2015 by a leading private equity firm. Mr. Moss previously served as Managing Director, Corporate Finance for a New York-based securities firm, where he advised companies on corporate strategy, financings and business development. Prior to that, he served as Managing Partner at a Seattle-based venture capital firm. Mr. Moss holds an MBA from Rice University and a BA in Economics from the University of California, San Diego. Mark W. Lowdell, PhD, FRCPath, FRSB, CSO Prof. Lowdell has been a Chief Scientific Officer and Chief Manufacturing Officer since the formation of the Company in September 2015. Prof. Lowdell is Professor of Cell and Tissue Therapy at University College London, where he has led a translational immunotherapy group since 1994. Since February 2009, Prof. Lowdell has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust. He received his PhD The Phoenix Partners in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist. Christopher J. Barnum, PhD, Director of Neuroscience Dr. Barnum is the Director of Neuroscience at INmune Bio, Inc. Dr. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academia and industry, including Emory University, FPRT Bio., SonosBio, and most recently Takeda Pharmaceuticals. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker- directed approach. Dr. Barnum has been working with XPro1595 for more than a decade, first at Emory University with Dr. Malú Tansey and subsequently as a consultant for FPRT Bio., Inc. and INmune Bio, before joining INmune Bio full time in 2018. Dr. Barnum’s research has been supported by NIH, The Michael J Fox Foundation, and the Alzheimer’s Association. He received his PhD in Neuroscience from Binghamton University. Joshua S. Schoonover, Esq., Assoc. General Counsel Mr. Schoonover is our in-house counsel, primarily focused on developing intellectual property rights for the Company, as well as managing various licenses and other agreements. Mr. Schoonover has over ten years of experience building and monetizing intellectual property portfolios. His experience also includes multiple transactions, including a recent nine-figure acquisition of a portfolio containing over 230 patent matters which Mr. Schoonover drafted and prosecuted. He received a JD from Western Sierra Law School and a BS in Chemical Physics from San Diego State University. Mr. Schoonover is a member of the State Bar of California and is licensed to practice before the United States Patent & Trademark Office, the Southern District of California and the 9th Circuit Court of Appeals. 4
Recommend
More recommend
